Edaravone: a new treatment for ALS on the horizon?

  title={Edaravone: a new treatment for ALS on the horizon?},
  author={Orla Hardiman and Leonard H. van den Berg},
  journal={The Lancet Neurology},

Paper Mentions

Interventional Clinical Trial
Given the role of adaptive immunity in ALS, the pathogenicity of some clostridial strains on motorneurons, the putative role of cyanobacteria in ALS development, and the increasing… Expand
ConditionsAmyotrophic Lateral Sclerosis
Innovating Clinical Trials for Amyotrophic Lateral Sclerosis
A flexible design framework is proposed which naturally adapts the trial duration when inaccurate assumptions are made at the design stage such as the enrollment or survival rate and may serve a blueprint for future clinical trials in this population of patients. Expand
Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
Analysis of long-term OS indicates that oral masitinib (4.5 mg/kg/day) could prolong survival by over 2 years as compared with placebo, provided that treatment starts prior to severe impairment of functionality. Expand
Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases
Clinical and research approaches that may facilitate more accurate diagnosis, monitoring, and treatment of pain as well as elucidation of the evolving nature of pain phenotypes in rare musculoskeletal or neuromuscular illnesses are described. Expand
Progress in progestin-based therapies for neurological disorders
Assessment of the scientific and clinical progress over decades of research into progesterone, progestins, and Nestorone as neuroprotective agents in MS, ALS, SCI, and stroke and recommendations for optimizing timing, dosage, and route of the drug regimen. Expand
A multidisciplinary clinic for amyotrophic lateral sclerosis patients in Northeast Mexico
It is described the processes involved in the evaluation of patients in an all day long session where ALS patients are evaluated by several professionals from different specialties specially trained in the needs of subjects living with this disorder. Expand
Amyotrophic Lateral Sclerosis Modifiers in Drosophila Reveal the Phospholipase D Pathway as a Potential Therapeutic Target
Two independent genome-wide screens for modifiers of degenerative phenotypes associated with the expression of transgenic constructs carrying familial ALS-causing alleles of FUS (hFUSR521C) and TDP-43 (hTDP- 43M337V) uncover a complex array of genes affecting either or both of the two strains. Expand
Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System
In this cohort study of data from 369 US veterans with documented or probable ALS, a significantly greater proportion of acute all-cause hospitalizations was associated with edaravone treatment and, among users receiving at least 6 months of treatment, an increased likelihood of ALS-related hospitalization was associatedwith edarvone treatment compared with riluzole-only treatment. Expand
Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina
Treatment access was limited but feasible and edaravone was well tolerated, while Adverse effects and the need of a special catheter for infusion were rare. Expand
Non-invasive characterization of amyotrophic lateral sclerosis in a hTDP-43A315T mouse model: A PET-MR study
The results reveal that disease- and age-related functional and neurochemical alterations, together with limited structural changes, occur in specific brain regions of transgenic TDP-43A315T mice, as compared to their healthy counterparts. Expand


Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
The primary efficacy outcome was the change in ALSFRS-R score from the baseline to 24 weeks (or at discontinuation if this was after the third cycle) after randomisation and the least-squares mean difference between groups was 2·49 (SE 0·76, 95% CI 0·99-3·98) in favour of edaravone. Expand
The changing picture of amyotrophic lateral sclerosis: lessons from European registers
Going forward, lessons learned from the collective experience of operating population-based ALS registers in Europe for over two decades are offered, focusing on register design, maintenance, identification and management of bias and the value of cross-national harmonisation and integration. Expand
Amyotrophic lateral sclerosis: moving towards a new classification system
A new strategy is needed to combine the benefits of a systematic approach to classification with the rich and varied phenotypic descriptions used in clinical practice to avoid confusion between diagnosis and phenotype. Expand
What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis
Results provide robust evidence that the ALSFRS-R should not be reported as a single combined score, but rather as domain specific subscores. Expand
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
The reduction of ALSFRS-R was smaller in the edaravone group than in the placebo group, but efficacy of edarvone for treatment of ALS was not demonstrated. Expand
Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice
The results indicate that edaravone was effective to slow symptom progression and motor neuron degeneration in the ALS model mice and these favorable actions might be attributable to the yet unidentified mechanism responsible for reducing the deposition of mutant SOD1. Expand
Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study)
  • H. Yoshino, A. Kimura
  • Medicine
  • Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
  • 2006
Data from the present study suggest that edaravone is safe and may delay the progression of functional motor disturbances by reducing oxidative stress in ALS patients. Expand